Tara Herrmann, PhD, MBA
About Tara Herrmann, PhD, MBA
Tara Herrmann, PhD, MBA, is the Clinical Trial Lead for Thoracic Cancers and Biomarkers at Bristol Myers Squibb, with extensive experience in oncology and scientific training.
Company
Tara Herrmann currently works at Bristol Myers Squibb. In her role, she leads clinical trials focused on Thoracic Cancers and Biomarkers. Bristol Myers Squibb is known for its extensive research and development in the field of oncology, and Herrmann's work contributes to the advancement of treatments in this critical area.
Title
Tara Herrmann, PhD, MBA, holds the title of Clinical Trial Lead, Thoracic Cancers and Biomarkers. This position involves overseeing and directing clinical trials, ensuring that they align with regulatory standards and scientific objectives in the study of thoracic cancers and related biomarkers.
Education and Expertise
Tara Herrmann earned her PhD in Immunology, Infectious Disease, and Inflammation from the University of Iowa, where she studied from 2001 to 2006. She also holds an MBA in International Business from American Military University, which she completed from 2014 to 2017. Herrmann received her BS in Biochemistry and Molecular Biology from The University of New Mexico, graduating in 2001, and studied Epidemiology in Public Health Practice at John Hopkins University. Her educational background is complemented by her professional specialization in solid tumors and biomarkers within oncology.
Professional Background
Before her current role at Bristol Myers Squibb, Tara Herrmann worked at Merck as Scientific Director of Medical Affairs, Oncology, from 2020 to 2021. She also served as Associate Director of Scientific Training, Thoracic Cancers, at AstraZeneca from 2018 to 2020. Prior to that, Herrmann was Director of Clinical Strategy for Solid Tumor Oncology at Medscape Education for five years and Scientific Director of Pulmonary Medicine and Allergy and Clinical Immunology at Medscape for four years. Her career also includes roles at RealCME, IME, LLC (A Division of Sudler & Hennessey), the University of Rochester Medical Center, and University of Iowa Hospitals and Clinics.
Focus on Thoracic Cancers and Biomarkers
In her capacity at Bristol Myers Squibb, Tara Herrmann is dedicated to clinical research in thoracic cancers and biomarkers. This focus is essential for the development of targeted therapies and improving patient outcomes in the field of oncology. Her current work supports the identification of biomarkers that can predict responses to therapies and help in personalizing treatment strategies for patients with thoracic cancers.